VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
Key Highlights
- ➤BiTAC-ADCs produced strong tumor regression at a single 3 mg/kg dose
- ➤BiTAC-ADC treatment showed no observed decrease in body weight
- ➤Single non-targeted component produced no significant tumor effect
- ➤BiTAC-ADCs demonstrated tumor-specific activation after systemic administration
- ➤In vitro data showed discrimination between cancer and healthy cells
Expert Statements
Christoph Erkel, Chief Scientific Officer at VERAXA
“These novel datasets on the BiTAC-ADC platform underline the rapid progress our team has made in demonstrating the potentially transformative safety benefits of BiTAC-ADCs compared to conventional ADCs.”
Christoph Erkel, Chief Scientific Officer at VERAXA
“While BiTAC-TCEs remain our priority, the rapid validation of our BiTAC-ADC concept bodes well for establishing a second pillar in our R&D and partnering strategy towards safer drugs for solid tumor patients.”
Paul Sauter, Senior Director and Department Head ADC Tech & Chemistry at VERAXA
“Demonstrating that BiTAC-ADCs can reach the tumor site following intravenous administration, induce a specific effect only upon arrival of both BiTAC components, and shrink the tumor in a living organism is a significant platform milestone and validates its underlying concept.”
In vivo data confirm activation of prodrug payload inside tumor cells following systemic administration of BiTAC-ADC molecules leading to potent anti-tumor activity
ZURICH, SWITZERLAND – October 13, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today presented first in vivo proof-of-concept data and additional in vitro data validating its novel BiTAC-ADC technology platform at the 17(th) World ADC Congress in San Diego, CA, USA. The in vivo data demonstrate that a systemically applied, single dose of the two-component BiTAC-ADC selectively triggered a tumor-specific response resulting in a significant reduction in tumor volume, while continuing to show differentiated safety features and the potential to overcome systemic toxicity, the primary limitation of current ADCs.
Get started
Create a free account to read the full story.